Sorafenib in Thyroid Cancer Patients: Learning From Toxicity

A recent review showed frequent reductions of sorafenib dose in the treatment of metastatic thyroid cancer because of toxicity consistent with the findings of the phase III DECISION trial and contrasting with the safety of sorafenib in other cancer populations. The unexpected excess of toxicity obse...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Huillard, Olivier, Blanchet, Benoit, Boudou-Rouquette, Pascaline, Thomas-Schoemann, Audrey, Wassermann, Johanna, Goldwasser, François
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AlphaMed Press 2014
Pynciau:
Letters to the Editor
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4122476/
https://ncbi.nlm.nih.gov/pubmed/25052452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0156
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg